The Effect of Betahistine on Body Weight in Obese Subjects

NCT ID: NCT00409305

Last Updated: 2015-04-21

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 280 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-01-31
• Study Completion Date: 2007-06-30

Brief Summary

The purpose of this study is to examine the effect that betahistine has on body weight in obese subjects.

Conditions

Obesity

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Interventions

Betahistine

Intervention Type: DRUG

Dietary counseling

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Signed written informed consent;
• Male or female subjects 18 to 65 years of age;
• Is obese with a BMI greater than or equal to 30 kg/m2 to less than or equal to 40 kg/m2;
• Has been obese for at least 1 year prior to screening; and
• If female, is nonlactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to randomization or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year) must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration.

Exclusion Criteria

• Has obesity of known endocrine origin (e.g., Cushing's disease, Addison's disease, hypothalamic tumor);
• Has a medical history (e.g., morbid childhood obesity) and/or physical characteristics (e.g., polydactyly) suggestive of genetic obesity (e.g., ob/ob genotype) or syndromatic obesity (e.g., Prader-Willi syndrome, Bardet Biedl syndrome);
• Previous surgical procedures for weight loss;
• Has had liposuction within 1 year before screening or is planning to have liposuction during the study;
• History of bulimia or evidence of laxative abuse;
• Has had a body weight loss of >4 kg in the 90 days prior to screening;
• Has taken drugs capable of influencing body weight 30 days prior to screening;
• Has recently started or plans on starting a smoking cessation program;
• Has had a major change in daily physical activity (e.g., initiation of an exercise program) or started a weight loss program within 90 days prior to screening;
• Is unwilling or unable to participate in a dietary program as part of the study;
• Is <80% compliant with study medication in the single-blind placebo run-in period;
• Has a clinically significant history or presence of any of the following conditions:
• Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities;
• Liver disease (irrespective of transaminase concentrations);
• Pheochromocytoma;
• Porphyria;
• Type 1 diabetes mellitus;
• Type 2 diabetes mellitus on treatment other than metformin monotherapy and/or diet with HbA1c less than or equal to 8%;
• Severe type 2 diabetes with history of ketoacidosis or diabetic ulcers, or presence of retinopathy, neuropathy, or nephropathy;
• Renal insufficiency defined as a serum creatinine greater than or equal to 1.5 mg/dL (133 µmol/L) at screening;
• Malignant disease within 5 years of screening;
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x ULN;
• Thyroid-stimulating hormone (TSH) outside of the normal range;
• Plans on having any surgery (elective or otherwise) during the course of the study;
• Has uncontrolled hypertension (sitting blood pressure >160/95 mmHg at screening or randomization), uncontrolled hyperlipidemia (triglycerides [TG] greater than or equal to 400 mg/dL or low-density lipoprotein cholesterol [LDL-C] >160 mg/dL), or uncontrolled diabetes (HbA1c >8%);
• History of asthma;
• History of peptic ulcers;
• History of HIV;
• History of undiagnosed allergy, severe allergy, or drug allergy, including history of anaphylaxis, angioedema, bronchospasm, or urticaria;
• Has clinical laboratory test values (chemistry, hematology, or urinalysis) judged to be clinically significant by the investigator;
• Has a physical examination or electrocardiogram (ECG) with significant abnormalities, as judged by the investigator;
• Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion could cause the subject to be noncompliant with study procedures;
• Has hypersensitivity to betahistine;
• Has psychiatric or neurological disorders requiring chronic medications (e.g., antidepressants), subjects are to be unlikely to have a major depressive episode (score of lees than or equal to 8) on The Harvard Department of Psychiatry and National Depression Screening Day Scale (THE HANDS) (See Appendix E);
• Chronic or as needed use of antihistamines;
• Has not been on a stable treatment regimen with any of the following medications for a minimum of 90 days prior to screening:
• Hormone replacement therapy;
• Oral contraceptives;
• Antihypertensive agents;
• Metformin;
• Lipid-lowering agents; or
• Thyroid replacement therapy;
• Has been treated over the past 60 days, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications;
• All prescription or over-the-counter agents taken for the purpose of weight reduction, including (but not limited to) the following anti obesity agents:
• Prescription drugs such as orlistat, sibutramine, and phentermine; or
• Over-the-counter antiobesity agents (e.g., herbal supplements or other alternative remedies such as Cortislim, Dexatrim, Acutrim);
• Psychotropic/neurological agents including the following:
• Antipsychotic agents (e.g., olanzapine, clozapine, risperidol, lithium, etc.).
• Antiepileptic agents (e.g., Topamax®, Zonegran®, valproate, carbamazepine); or
• Antidepressant agents including the following: monoamine oxidase inhibitors, bupropion (Wellbutrin®, Zyban®), tricyclic antidepressants, and tetracyclic antidepressants; and selective serotonin reuptake inhibitors (e.g., Prozac®, Paxil®, Zoloft®, etc.);
• Systemic steroids administered by oral, intravenous, or intramuscular route;
• Drugs that directly affect gastrointestinal motility (e.g., Reglan® and Propulsid®, and chronic [taken for more than 10 days within a 6-month period] macrolide antibiotics such as erythromycin and newer derivatives);
• Calcitonin (e.g., Miacalcin®);
• Insulin;
• Exenatide (Byetta);
• Sulfonylureas (e.g., Diamicron, Amaryl, Glucotrol, Micronase); or Meglitinides (e.g., Starlix, Prandin)
• Has received any investigational drug within 90 days of screening;
• Receipt of any investigational treatment (drug or device) within 90 days prior to screening;
• Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or
• Is employed by OBEcure Ltd.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

OBEcure Ltd.

INDUSTRY

Sponsor Role: lead

Principal Investigators

Andrew Ahmann, MD

Role: PRINCIPAL_INVESTIGATOR

Covance CRU, Inc

Louis Aronne, MD

Role: PRINCIPAL_INVESTIGATOR

Comprehensive Weight Control Program

Harold Bays, MD

Role: PRINCIPAL_INVESTIGATOR

L-Marc Research Center

Norman Fishman, MD

Role: PRINCIPAL_INVESTIGATOR

Diabetes & Endocrinology Specialists

Ken Fujioka, MD

Role: PRINCIPAL_INVESTIGATOR

Scripps Clinic, Nutrition Metabolic Research

Jeffrey Geohas, MD

Role: STUDY_DIRECTOR

Radiant Research, Inc

Frank Greenway, MD

Role: PRINCIPAL_INVESTIGATOR

Pennington Biodmedical Research Center

Dean Kereiakes, MD

Role: PRINCIPAL_INVESTIGATOR

Lindner Clinical Trial Center

Diane Krieger, MD

Role: PRINCIPAL_INVESTIGATOR

Miami Research Associates, Nutrition Division

Robert Kushner, MD

Role: PRINCIPAL_INVESTIGATOR

NCCR

Thomas Moretto, MD

Role: PRINCIPAL_INVESTIGATOR

American Health Network

Monica Pierson, MD

Role: PRINCIPAL_INVESTIGATOR

Radiant Research

Sherwyn Schwartz, MD

Role: PRINCIPAL_INVESTIGATOR

Diabetes & Glandular Disease Research Associates

Diane Smith, MD

Role: PRINCIPAL_INVESTIGATOR

CSRA Partners in Health

Philip Toth, MD

Role: PRINCIPAL_INVESTIGATOR

Midwest Institute for Clinical Research

Mervyn Weerasinghe, MD

Role: PRINCIPAL_INVESTIGATOR

Rochester Clinical Research

Richard Weinstein, MD

Role: PRINCIPAL_INVESTIGATOR

Diablo Clinical Research

Lisa Wright, MD

Role: PRINCIPAL_INVESTIGATOR

Cahaba Research, Inc

James Zavoral, MD

Role: PRINCIPAL_INVESTIGATOR

Radiant Research, Inc.

Nir Barak, MD

Role: STUDY_DIRECTOR

OBEcure Ltd.

Yaffa Beck, PhD

Role: STUDY_CHAIR

OBEcure Ltd.

Ami Eyal, MD

Role: STUDY_CHAIR

OBEcure Ltd.

Locations

Cahaba Research, Inc.

Birmingham, Alabama, United States

Scripps Clinic, Nutrition Metabolic Research

San Diego, California, United States

Diablo Clinical Research, Inc.

Walnut Creek, California, United States

Miami Research Associates, Inc., Nutrition Division

Miami, Florida, United States

CSRA Partners in Health, Inc.

Augusta, Georgia, United States

Radiant Research, Inc.

Chicago, Illinois, United States

NCCR

Chicago, Illinois, United States

American Health Network

Indianapolis, Indiana, United States

Midwest Institute for Clinical Research

Indianapolis, Indiana, United States

Radiant Research, Inc.

Overland Park, Kansas, United States

L-MARC Research Center

Louisville, Kentucky, United States

Pennington Biomedical Research Center

Baton Rouge, Louisiana, United States

Radiant Research, Inc.

Edina, Minnesota, United States

Diabetes & Endocrinology Specialists

Chesterfield, Missouri, United States

Comprehensive Weight Control Program

New York, New York, United States

Rochester Clinical Research, Inc.

Rochester, New York, United States

Lindner Clinical Trial Center

Cincinnati, Ohio, United States

Covance CRU, Inc.

Portland, Oregon, United States

Diabetes & Glandular Disease Research Associates, Inc.

San Antonio, Texas, United States

Countries

United States

Other Identifiers

BET201

Identifier Type: -

Identifier Source: org_study_id